Ampio Financial Statements From 2010 to 2024
| AMPEDelisted Stock | USD 0.24 0.01 4.35% |
Check Ampio Pharm financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ampio Pharm's main balance sheet or income statement drivers, such as , as well as many indicators such as . Ampio financial statements analysis is a perfect complement when working with Ampio Pharm Valuation or Volatility modules.
Ampio |
Ampio Pharm Company Shares Owned By Insiders Analysis
Ampio Pharm's Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Ampio Pharm Shares Owned By Insiders | 1.56 % |
Most of Ampio Pharm's fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ampio Pharm is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
CompetitionBased on the latest financial disclosure, 1.561% of Ampio Pharm are shares owned by insiders. This is 89.72% lower than that of the Pharmaceuticals sector and 88.99% lower than that of the Health Care industry. The shares owned by insiders for all United States stocks is 84.53% higher than that of the company.
Ampio Pharm Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Ampio Pharm's current stock value. Our valuation model uses many indicators to compare Ampio Pharm value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Ampio Pharm competition to find correlations between indicators driving Ampio Pharm's intrinsic value. More Info.Ampio Pharm is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Ampio Pharm's earnings, one of the primary drivers of an investment's value.About Ampio Pharm Financial Statements
Ampio Pharm stakeholders use historical fundamental indicators, such as Ampio Pharm's revenue or net income, to determine how well the company is positioned to perform in the future. Although Ampio Pharm investors may analyze each financial statement separately, they are all interrelated. For example, changes in Ampio Pharm's assets and liabilities are reflected in the revenues and expenses on Ampio Pharm's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Ampio Pharm. Please read more on our technical analysis and fundamental analysis pages.
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19 and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. Ampio Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 18 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Consideration for investing in Ampio Pink Sheet
If you are still planning to invest in Ampio Pharm check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ampio Pharm's history and understand the potential risks before investing.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |